Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases. ...